Elan Corp plc  (ELN) Trade Now »     Rate ELN  -  Discuss ELN  -  Add to Watch List        

Home

Analysis & Videos

Quotes

Bull or Bear

Discuss

ELN: Bull or Bear?

From:    SocialPicks  |  Blogsphere  |  All

SocialPicks Community

Newron Pharma ...Very attractive CNS-Pipeline ELN

N/A

+2.15% in 193 days Newron Pharma (NRWN.SW) Listed on Swiss Exchange M-Cap : 99,97 Mio CHF ( 88,26 Mio US$ ) Cash : 62,38 Mio CHF ( 55,07 Mio US$ ) Price : 16 CHF Shares Out : 6,03 Mio Pipeline http://www.newron.com/uploads/pipeline_111November3.pdf Safinamide Significantly Improved Motor Function in Patients with Advanced Parkinson's Disease in a Phase III Pivotal Trial <> <>http://www.newron.com/uploads/SAfinamidePIIIresultsNew... Continue reading »

Newron Pharma ...Very attractive CNS-Pipeline ELN

N/A

+0.00% in 0 minute (closed on 05/13/09) Newron Pharma (NRWN.SW) Listed on Swiss Exchange M-Cap : 99,97 Mio CHF ( 88,26 Mio US$ ) Cash : 62,38 Mio CHF ( 55,07 Mio US$ ) Price : 16 CHF Shares Out : 6,03 Mio Pipeline http://www.newron.com/uploads/pipeline_111November3.pdf Safinamide Significantly Improved Motor Function in Patients with Advanced Parkinson's Disease in a Phase III Pivotal Trial <> <>http://www.newron.com/uploads/SAfinamidePIIIresultsNew... Continue reading »

Biogen Reports Another PML Case in Tysabri Patient ELN

73%

+3.11% in 387 days Biogen Reports Another PML Case in Tysabri Patient <> After the market close, Biogen (BIIB) filed an 8-K with the SEC reporting a new case of the potentially fatal brain disease known as PML or progressive multifocal leukoencephalopathy in a patient receiving their multiple sclerosis [MS] drug Tysabri, adding to the two new cases which were reported previously in July. Biogen is currently trading down by about 15% after hours while marketing partner Elan (ELN) is down by about 25% as of 5:15 PM. The news adds more uncertainty to Tysabri, which was removed from th... Continue reading »

Biogen Reports Another PML Case in Tysabri Patient ELN

73%

+0.00% in 3 hours (closed on 10/30/08) Biogen Reports Another PML Case in Tysabri Patient <> After the market close, Biogen (BIIB) filed an 8-K with the SEC reporting a new case of the potentially fatal brain disease known as PML or progressive multifocal leukoencephalopathy in a patient receiving their multiple sclerosis [MS] drug Tysabri, adding to the two new cases which were reported previously in July. Biogen is currently trading down by about 15% after hours while marketing partner Elan (ELN) is down by about 25% as of 5:15 PM. The news adds more uncertainty to Tysabri, which was removed from th... Continue reading »

Clarity on Tysabri Makes Elan and Biogen a Buy ELN

50%

-48.77% in 441 days FDA Table of Potential Drug Risks - from Adverse Event Reporting System (AERS) <> The FDA has published a table with the names of products and potential signals of serious risks and/or new safety information identified for these products during 1Q08 in the AERS database. The FDA notes that patients should not stop taking these medications and should consult their prescriber with any questions as the agency will investigate each of the claims further before taking action or issuing more definitive statements on the reported concerns. Some highlights from this table of produ... Continue reading »

From the Blogosphere

Unusual 11 Mid-Day Movers 10/23: AMZN, SCSS, ALGN, EPAY Higher; ELN, SNV, CBRX, STSA Lower

Amazon.com, Inc. (NASDAQ: AMZN) <font>24.2% HIGHER;</font> reports Q3 EPS of $0.45, 12 cents better than the analyst estimate of $0.33. Revenue for the quarter was $5.45 billion, which compares to the estimate of $5.03 billion. Sees Q4 sales of $8.125 - $9.125 billion, versus the consensus of $8.11 billion.Elan (NYSE: ELN) <font>19.6% LOWER;</font> European regulators have begun their risk/reward analyst for Elan and Biogen's (Nasdaq: BIIB) Tysabri. Click here for the full report.Synovus Financial Corp. (NYSE: SNV) <font>18.5% LOWER;</font> reports Q3 loss of $1.27, versus the analyst estim... Continue reading »

Morning Movers 10/23: AMZN, CPWR, EPAY, ALGN, HWAY, SCSS, ACO Higher; ELN, SNV, CBRX, RMTR, STSA, DVAX Lower

Amazon.com, Inc. (NASDAQ: AMZN) <font>22.1% HIGHER;</font> reports Q3 EPS of $0.45, 12 cents better than the analyst estimate of $0.33. Revenue for the quarter was $5.45 billion, which compares to the estimate of $5.03 billion. Sees Q4 sales of $8.125 - $9.125 billion, versus the consensus of $8.11 billion.Elan (NYSE: ELN) <font>21% LOWER;</font> European regulators have begun their risk/reward analyst for Elan and Biogen's (Nasdaq: BIIB) Tysabri.Synovus Financial Corp. (NYSE: SNV) <font>21.2% LOWER;</font> reports Q3 loss of $1.27, versus the analyst estimate of ($0.67). Columbia Laborator... Continue reading »

Trading Radar for 10/21: Boeing (BA), eBay (EBAY), Wells Fargo (WFC), US Bancorp (USB), Eli Lilly (ELY), St. Jude Medical (STJ) Report

The Trading Radar highlights key earnings and economic announcements for tomorrow's trading session:<u>Before Market Opens:</u>Earnings:Air Products and Chemicals Inc (NYSE: APD) – consensus EPS $1.12Allegheny Technologies (NYSE: ATI) – consensus EPS $0.03Altria Group, Inc. (NYSE: MO) – consensus EPS $0.47AMB Property Corporation (NYSE: AMB) – consensus EPS $0.33Arkansas Best Corp. (NASDAQ: ABFS) – consensus loss $0.36ATMI (NASDAQ: ATMI) – consensus EPS $0.09Community Trust (NASDAQ: CTBI) – consensus EPS $0.44Cullen/Frost Bankers (NYSE: CFR) – consensus EPS $0.77Dice Holdings, Inc (NYSE: DH... Continue reading »

Deal Modification for Elan, J&J

28%

We believe the dispute between Elan Corp. (ELN) and its US partner Biogen Idec (BIIB) over the multiple-sclerosis drug Tysabri has been resolved at last. Continue reading »

Deal Modification for Elan, J&J

We believe the dispute between Elan Corp. (ELN) and its US partner Biogen Idec (BIIB) over the multiple-sclerosis drug Tysabri has been resolved at last. Continue reading »

... more »  

None of the information contained on SocialPicks.com constitutes a recommendation by SocialPicks or its users that any particular security, portfolio of securities, transaction, or investment strategy is suitable for any specific person. SocialPicks is not responsible for the posts, discussions, and recommendations of the users on the Site. SocialPicks does not provide investment advice. You must make your own independent decisions regarding any security, portfolio of securities, transaction, or investment strategy mentioned on the website. SocialPicks' users' past results are not necessarily indicative of future performance. Neither SocialPicks nor any of its users guarantees any specific outcome or profit, and you should be aware of the real risk of loss in following any strategy or investments discussed on the website. You understand and agree that you use the Site and Services at your own discretion and risk and that you will be solely responsible for any damages that arise from such use. Before acting on any information contained on the website, you should consider whether it is suitable for your particular circumstances and strongly consider seeking advice from your own financial or investment adviser.